268 related articles for article (PubMed ID: 29218680)
21. Valbenazine: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(10):1123-1129. PubMed ID: 28578484
[TBL] [Abstract][Full Text] [Related]
22. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
23. Valbenazine for Tardive Dyskinesia.
Freudenreich O; Remington G
Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
[TBL] [Abstract][Full Text] [Related]
24. Valbenazine for the treatment of tardive dyskinesia.
Müller T
Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
Nagano M; Susuta Y; Masui H; Watanabe Y; Watanabe K
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):107-116. PubMed ID: 38421921
[TBL] [Abstract][Full Text] [Related]
26. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
Marder SR; Singer C; Lindenmayer JP; Tanner CM; Comella CL; Verghese C; Jimenez R; Liang GS; Burke J; OʼBrien CF
J Clin Psychopharmacol; 2019; 39(6):620-627. PubMed ID: 31688452
[TBL] [Abstract][Full Text] [Related]
27. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
[TBL] [Abstract][Full Text] [Related]
28. Valbenazine for the treatment of tardive dyskinesia.
Barquero N
Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
[TBL] [Abstract][Full Text] [Related]
29. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
30. Valbenazine (Ingrezza) for tardive dyskinesia.
Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
[No Abstract] [Full Text] [Related]
31. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
[TBL] [Abstract][Full Text] [Related]
32. Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective.
Josiassen RC; Filmyer DM; Gillean J; Shah SS; Dietterich TE; Shaughnessy RA
Am J Case Rep; 2017 Nov; 18():1185-1189. PubMed ID: 29114100
[TBL] [Abstract][Full Text] [Related]
33. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV
N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481
[No Abstract] [Full Text] [Related]
34. Valbenazine in the treatment of tardive dyskinesia.
Witek N; Comella C
Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
[TBL] [Abstract][Full Text] [Related]
35. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
Müller T
Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
[TBL] [Abstract][Full Text] [Related]
36. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
37. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stahl SM
CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
[TBL] [Abstract][Full Text] [Related]
38. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
[TBL] [Abstract][Full Text] [Related]
40. Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.
Correll CU; Citrome L; Singer C; Lindenmayer JP; Zinger C; Liang G; Dunayevich E; Marder SR
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):353-361. PubMed ID: 38767901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]